Precision BioSciences, Inc.

Precision Biosciences Inc. is a biotechnology company that focuses on the development of gene editing technologies aimed at improving human health. Its primary function is to leverage its proprietary ARCUS genome editing platform to create therapeutic solutions for genetically-defined diseases. This cutting-edge technology is notable for its precision and versatility, allowing for highly specific edits to DNA sequences. Precision Biosciences is particularly impactful in the healthcare sector, targeting areas such as oncology and genetic disorders. The company develops allogeneic CAR T cell therapies, which are designed to treat cancer with off-the-shelf cell products, aiming to overcome limitations associated with autologous therapies. As a player in the biotechnology field, Precision Biosciences contributes to advancing personalized medicine and precision therapeutics, holding a vital role in the ongoing innovation within the biopharmaceutical market. Founded in 2006 and based in Durham, North Carolina, the company is at the forefront of biotechnological advancements, striving to address significant unmet medical needs through genetic and cellular solutions.